3 terminated, 2 completed, 1 active not recruiting, 1 not yet recruiting. 7 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Terminated 3, Completed 2, Active not recruiting 1, Not yet recruiting 1 |
| Phase 3 | 2 | Terminated 2 |
| Phase 1 | 1 | Completed 1 |
Follow Usher Syndrome Type 2: new trials by email Literature Review of Usher Syndrome Type 2 trials Research Report on Usher Syndrome Type 2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Long-Term Safety of Ultevursen in Participants With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene No intervention, will not receive any active study intervention, Intravitreal Injection of Ultevursen - Retinitis Pigmentosa (RP), Usher Syndrome Type 2 | Phase 2 | Not yet recruiting | Laboratoires Thea | 81 | 2026-10-05 | 2026-09-01 |
| Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene Intravitreal Injection of Ultevursen, No intervention, will not receive any active study intervention - Retinitis Pigmentosa (RP), Usher Syndrome Type 2 | Phase 2 | Active not recruiting | Laboratoires Thea | 81 | 2024-12-11 | 2026-07-09 |
| Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste) QR-421a, Sham-procedure - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 2 / Phase 3 | Terminated | Laboratoires Thea | 5 | 2021-12-15 | 2024-08-07 |
| Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius) Ultevursen, Sham-procedure - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 2 / Phase 3 | Terminated | Laboratoires Thea | 7 | 2021-12-08 | 2024-07-12 |
| An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa RNA antisense oligonucleotide for intravitreal injection - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 2 | Terminated | Laboratoires Thea | 21 | 2021-09-16 | 2024-08-07 |
| Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene QR-421a, Sham-procedure (dose cohort 1&2 only) - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 1 / Phase 2 | Completed | ProQR Therapeutics | 20 | 2019-03-06 | 2022-04-20 |
| Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa NT-501, Sham - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 2 | Completed | Neurotech Pharmaceuticals | 22 | 2012-01-01 | 2023-02-14 |
Retinitis Pigmentosa (7) · Usher Syndromes (7) · Retinal Diseases (6) · Vision Disorders (6) · Eye Abnormalities (5) · Eye Diseases, Hereditary (5) · Eye Diseases (4) · Genetic Diseases, Inborn (1) · Night Blindness (1)
Abnormalities, Multiple (7) · Blindness (7) · Congenital Abnormalities (7) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (7) · Deaf-Blind Disorders (7) · Deafness (7) · Ear Diseases (7) · Hearing Disorders (7) · Hearing Loss (7) · Hearing Loss, Sensorineural (7) · Nervous System Diseases (7) · Neurologic Manifestations (7) · Otorhinolaryngologic Diseases (7) · Pathological Conditions, Signs and Symptoms (7) · Retinal Degeneration (7)
Intravitreal Injections (4) · Ciliary Neurotrophic Factor (1) · Electroconvulsive Therapy (1) · salicylhydroxamic acid (1)
Laboratoires Thea (5) · Neurotech Pharmaceuticals (1) · ProQR Therapeutics (1)
United States (6) · Canada (3) · France (3) · United Kingdom (3) · Germany (2) · Netherlands (2) · Belgium (1) · Brazil (1) · Denmark (1) · Italy (1)
PMID 31215818, PMID 37418643, PMID 40339601
2018 (1)